A166480 Stock Overview
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CORESTEMCHEMON Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,700.00 |
| 52 Week High | ₩13,440.00 |
| 52 Week Low | ₩5,250.00 |
| Beta | 0.77 |
| 1 Month Change | 17.59% |
| 3 Month Change | 62.40% |
| 1 Year Change | 55.26% |
| 3 Year Change | -32.09% |
| 5 Year Change | -6.96% |
| Change since IPO | -69.47% |
Recent News & Updates
Recent updates
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry
Mar 05
Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?
Apr 12If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns
Feb 16Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?
Dec 25Shareholder Returns
| A166480 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 30.5% | -0.6% | -2.4% |
| 1Y | 55.3% | 2.4% | 1.9% |
Return vs Industry: A166480 exceeded the KR Biotechs industry which returned -3.5% over the past year.
Return vs Market: A166480 exceeded the KR Market which returned -1% over the past year.
Price Volatility
| A166480 volatility | |
|---|---|
| A166480 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A166480's share price has been volatile over the past 3 months.
Volatility Over Time: A166480's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 77 | Kyung-Suk Kim | www.corestem.com |
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases.
CORESTEMCHEMON Inc. Fundamentals Summary
| A166480 fundamental statistics | |
|---|---|
| Market cap | ₩271.91b |
| Earnings (TTM) | -₩17.67b |
| Revenue (TTM) | ₩33.66b |
8.1x
P/S Ratio-15.4x
P/E RatioIs A166480 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A166480 income statement (TTM) | |
|---|---|
| Revenue | ₩33.66b |
| Cost of Revenue | ₩30.25b |
| Gross Profit | ₩3.41b |
| Other Expenses | ₩21.08b |
| Earnings | -₩17.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -825.39 |
| Gross Margin | 10.14% |
| Net Profit Margin | -52.50% |
| Debt/Equity Ratio | 162.5% |
How did A166480 perform over the long term?
See historical performance and comparison